跳至主要内容
临床试验/JPRN-UMIN000011976
JPRN-UMIN000011976已完成未知

Observation study to examine the efficacy of 500mg Fluvestrant that targets ER(+) postmenopausal metastatic breast cancer patients (>1st line). - PerSeus -BC03

PerSeUS:Perpetual Study estimated -by United Sections in Gifu0 个研究点开始时间: 2013年10月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1.Life threatening including large liver metastasis, larege brain metastasis, systematic inflammatory lymphangitis in lung. 2.Inflammatory breast cancer 3.Previous therapy by Fluvestrant. 4.Patients who accetted >4th ET. 5. Allergy to Fluvestrant. 6.Patients considered ineligible by the attending physician.

研究者

发起方
PerSeUS:Perpetual Study estimated -by United Sections in Gifu

相似试验